Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE...

por Nyström, Thomas, Toresson Grip, Emilie, Gunnarsson, Joel, Casajust, Paula, Karlsdotter, Kristina, Skogsberg, Josefin, Ustyugova, Anastasia
Publicado 2022

Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality

por Persson, Sofie, Nilsson, Kristoffer, Karlsdotter, Kristina, Skogsberg, Josefin, Gustavsson, Staffan, Jendle, Johan, Steen Carlsson, Katarina
Publicado 2022

Disease Burden and Healthcare Costs for T2D Patients With and Without Established Cardiovascular Disease in Sweden: A Retrospective Cohort Study

por Bernfort, Lars, Husberg, Magnus, Wiréhn, Ann-Britt, Rosenqvist, Ulf, Gustavsson, Staffan, Karlsdotter, Kristina, Levin, Lars-Åke
Publicado 2020

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden

por Bernfort, Lars, Husberg, Magnus, Wiréhn, Ann-Britt, Rosenqvist, Ulf, Gustavsson, Staffan, Karlsdotter, Kristina, Levin, Lars-Åke
Publicado 2020

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

por Nilsson, Kristoffer, Andersson, Emelie, Persson, Sofie, Karlsdotter, Kristina, Skogsberg, Josefin, Gustavsson, Staffan, Jendle, Johan, Steen Carlsson, Katarina
Publicado 2022